CN116688212B - III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof - Google Patents
III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof Download PDFInfo
- Publication number
- CN116688212B CN116688212B CN202310841771.2A CN202310841771A CN116688212B CN 116688212 B CN116688212 B CN 116688212B CN 202310841771 A CN202310841771 A CN 202310841771A CN 116688212 B CN116688212 B CN 116688212B
- Authority
- CN
- China
- Prior art keywords
- recombinant
- mixture
- iii
- collagen
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 139
- 108010035532 Collagen Proteins 0.000 title claims abstract description 139
- 229920001436 collagen Polymers 0.000 title claims abstract description 139
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 92
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 44
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229960001631 carbomer Drugs 0.000 claims abstract description 42
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 30
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 30
- 239000000230 xanthan gum Substances 0.000 claims abstract description 30
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 30
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 28
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 28
- 229940074409 trehalose dihydrate Drugs 0.000 claims abstract description 28
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 230000008439 repair process Effects 0.000 claims abstract description 6
- 239000008213 purified water Substances 0.000 claims description 54
- 229920001542 oligosaccharide Polymers 0.000 claims description 34
- 235000014620 theaflavin Nutrition 0.000 claims description 33
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims description 29
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims description 29
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims description 29
- 229940026509 theaflavin Drugs 0.000 claims description 29
- -1 alginate oligosaccharides Chemical class 0.000 claims description 28
- 235000011187 glycerol Nutrition 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 27
- 229940072056 alginate Drugs 0.000 claims description 26
- 235000010443 alginic acid Nutrition 0.000 claims description 26
- 229920000615 alginic acid Polymers 0.000 claims description 26
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 23
- 238000005303 weighing Methods 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 10
- 241000199919 Phaeophyceae Species 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 102000001187 Collagen Type III Human genes 0.000 claims 1
- 108010069502 Collagen Type III Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 34
- 206010052428 Wound Diseases 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 21
- 230000029663 wound healing Effects 0.000 abstract description 11
- 230000019612 pigmentation Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000036573 scar formation Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract description 3
- 230000006866 deterioration Effects 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 238000004904 shortening Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000035876 healing Effects 0.000 description 8
- 239000004745 nonwoven fabric Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 7
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 6
- 235000012734 epicatechin Nutrition 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 5
- 206010072170 Skin wound Diseases 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940015975 1,2-hexanediol Drugs 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000426 Microplastic Polymers 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention belongs to the technical field of biology and medicine, and particularly relates to a III type recombinant collagen dressing with an anti-aging repairing effect, and a preparation method and application thereof. The III type recombinant collagen dressing comprises the following raw materials: recombinant humanized collagen III, D- (+) -trehalose dihydrate, carbomer, xanthan gum, butylene glycol, glycerol, triethanolamine. The traditional Chinese medicine composition has the effects of shortening the course of disease, promoting wound healing and skin repair, reducing pigmentation and scar formation after inflammation, simultaneously playing a role in moisturizing the wound and repairing and resisting skin; further, the storage time of the dressing can be increased, and the risk of deterioration caused by the dressing being in a water-containing state can be reduced.
Description
Technical Field
The invention belongs to the technical field of biology and medicine, and particularly relates to a III type recombinant collagen dressing with an anti-aging repairing effect, and a preparation method and application thereof.
Background
Superficial abrasion, cutting wounds, small wounds, laser/photon/fruit acid skin replacement/micro-plastic surgery are clinically common skin injuries, and if the wound surface is improperly treated, the skin wounds can be infected by microorganisms, sometimes go deep into the tissues, cause tissue necrosis, and seriously endanger life. Therefore, when superficial damage occurs to the skin, debridement and protection should be performed in time. At present, the wound is clinically treated by a traditional method, and is covered by cotton gauze after debridement treatment by using disinfectants such as iodophor, hydrogen peroxide or physiological saline. The traditional gauze dressing has soft texture, strong absorption capacity, can prevent wound surface from liquid seepage accumulation, and has a certain protection effect on the wound surface. However, as one goes deep into the study of wound healing, it is recognized that the purpose of using a dressing is far more than to cover the wound surface, and that the dressing must also assist in wound healing. Previous views suggest that it is desirable to create a dry environment for the wound as much as possible, reducing the chance of infection and facilitating wound healing. However, recent studies have shown that wounds heal faster in a moist environment. Then, the traditional skin dressing has the limitations that the wound healing is not promoted, the moisture retention is not realized, granulation tissues are easy to grow into meshes of gauze to cause adhesion and crusting, secondary injury is easy to be caused to the wound during dressing change, and the problems that the focus is easy to form scars after healing and the like exist.
Chinese patent application CN116019965a discloses a collagen film dressing and its preparation method, comprising the following raw materials: III type recombinant humanized collagen, modified chitosan, an oil phase carrier, polyalcohol, preservative, modified soybean protein isolate, aloe fermentation broth, modified hyaluronic acid, traditional Chinese medicine extract and water, and the collagen film dressing provided by the III type recombinant humanized collagen has good biological functions by adding III type recombinant humanized collagen, and is beneficial to promoting wound healing and tissue repair of human bodies; the modified chitosan is added, so that the modified chitosan has a rich pore structure, a large specific surface area, and is fully mixed and crosslinked with other components to form a stable three-dimensional gel network, the mechanical property and the adhesive property of the film dressing can be improved, and the modified isolated protein is added, so that the solubility, the gel property and the emulsifying property of the soybean isolated protein are improved, and the modified chitosan is synergistic with the modified chitosan to further improve the mechanical property of the film dressing. However, the patent application does not disclose or teach what benefits are achieved in terms of reducing inflammation and scar formation, repairing anti-aging effects, etc.
Chinese patent application CN115998939A discloses a medical recombinant III type humanized collagen patch, which comprises recombinant human collagen, sodium hyaluronate, glycerol, xanthan gum, glyceryl caprylate, octanoic acid, 1,2 hexanediol, purified water, non-woven fabrics and medical aluminum film bags, wherein the dressing is claimed to inhibit and relieve skin inflammatory reactions caused by dermatitis, sensitive skin, acne, laser treatment and other reasons, promote wound healing and skin repair, shorten the course of disease, and reduce the risk of pigmentation and scar formation after inflammation. The patent application focuses on mechanical properties and claims other properties are not studied.
In view of the above, the invention provides a III type recombinant collagen dressing with repairing and anti-aging effects, and a preparation method and application thereof. Make up the deficiency of the traditional skin dressing, achieve the effects of shortening the course of disease, promoting wound healing and skin repair, reducing pigmentation and scar formation after inflammation, simultaneously playing a role in moisturizing the wound, and having the effects of repairing and resisting aging on the skin; further, the storage time of the dressing can be increased, and the risk of deterioration caused by the dressing being in a water-containing state can be reduced.
Disclosure of Invention
In order to overcome the technical problems, the invention provides a III type recombinant collagen dressing. The traditional Chinese medicine composition can effectively solve the problems, shorten the course of disease, promote wound healing and skin repair, reduce pigmentation and scar formation after inflammation, and simultaneously has the effects of moisturizing the wound and repairing and resisting the skin; further, the storage time of the dressing can be increased, and the risk of deterioration caused by the dressing being in a water-containing state can be reduced.
In order to achieve the above object, the technical scheme provided by the invention is as follows:
the invention provides a III type recombinant collagen dressing with repairing and anti-aging effects, which comprises the following raw materials:
recombinant humanized collagen III, D- (+) -trehalose dihydrate, carbomer, xanthan gum, butylene glycol, glycerol, triethanolamine.
Preferably, the type III recombinant collagen dressing comprises the following raw materials in parts by weight:
0.05-0.1 part of recombinant III-type humanized collagen, 0.15-1 part of D- (+) -trehalose dihydrate, 0.15-0.5 part of carbomer, 0.1-1 part of xanthan gum, 1-5 parts of butanediol, 1-5 parts of glycerol, 0.1-0.5 part of triethanolamine and 90-180 parts of purified water.
Preferably, the type III recombinant collagen dressing comprises the following raw materials in parts by weight:
0.05-0.09 part of recombinant III-type humanized collagen, 0.15-0.5 part of D- (+) -trehalose dihydrate, 0.15-0.45 part of carbomer, 0.1-0.5 part of xanthan gum, 2-3 parts of butanediol, 1-3 parts of glycerol, 0.2-0.4 part of triethanolamine and 92-150 parts of purified water.
The invention also aims to provide a preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects, which comprises the following steps:
(1) Taking part of formula amount of purified water, dissolving the formula amount of recombinant III type humanized collagen to prepare a recombinant III type humanized collagen solution for later use;
(2) Separately weighing carbomer and the residual formula amount of purified water, adding the carbomer into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating, homogenizing and preserving heat to obtain a mixture 3;
(5) Adding triethanolamine into the mixture 3, and stirring to obtain a mixture 4;
(6) Adding the recombinant III type humanized collagen solution in the step (1) into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution; and adding the base solution into a carrier to prepare the III type recombinant collagen dressing.
Preferably, in (3), the stirring is performed at 600-800r/min for 3-5min at normal temperature.
Preferably, in (4), the heating is to 80-95 ℃, preferably 92 ℃.
Preferably, in (4), the incubation is for 30-60min.
Preferably, in (5), the triethanolamine is added after the temperature of mixture 3 is reduced to 50-60 ℃.
Preferably, in (6), the recombinant type III humanized collagen solution is added when the temperature of the mixture 4 is reduced to less than 45 ℃.
Preferably, the weight ratio of the recombinant III type humanized collagen to the purified water in the recombinant III type humanized collagen solution is 0.05-0.1:30.
the invention also aims to provide a preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects, which comprises the following raw materials: recombinant humanized collagen III, D- (+) -trehalose dihydrate, carbomer, xanthan gum, butylene glycol, glycerol, triethanolamine, theaflavin, and brown alginate oligosaccharides.
Preferably, the type III recombinant collagen dressing comprises the following raw materials in parts by weight:
0.05-0.1 part of recombinant III-type humanized collagen, 0.15-1 part of D- (+) -trehalose dihydrate, 0.01-0.05 part of theaflavin, 0.05-0.2 part of brown alginate oligosaccharides, 0.15-0.5 part of carbomer, 0.1-1 part of xanthan gum, 1-5 parts of butanediol, 1-5 parts of glycerol, 0.1-0.5 part of triethanolamine and 90-180 parts of purified water.
Preferably, the type III recombinant collagen dressing comprises the following raw materials in parts by weight:
0.05-0.09 part of recombinant III-type humanized collagen, 0.15-0.5 part of D- (+) -trehalose dihydrate, 0.01-0.03 part of theaflavin, 0.05-0.1 part of brown algae oligosaccharide, 0.15-0.45 part of carbomer, 0.1-0.5 part of xanthan gum, 2-3 parts of butanediol, 1-3 parts of glycerin, 0.2-0.4 part of triethanolamine and 92-150 parts of purified water.
The invention also aims to provide a III type recombinant collagen dressing with repairing and anti-aging effects, which comprises the following steps:
(1) Taking part of purified water, dissolving recombinant III type humanized collagen in a prescription amount, and preparing a recombinant III type humanized collagen solution for later use;
(2) Respectively weighing carbomer, theaflavin, brown algae oligosaccharides and the remaining formula amount of purified water, sequentially adding carbomer, theaflavin and brown algae oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating, homogenizing and preserving heat to obtain a mixture 3;
(5) Adding triethanolamine into the mixture 3, and stirring to obtain a mixture 4;
(6) Adding the recombinant III type humanized collagen solution in the step (1) into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution; and adding the base solution into a carrier to prepare the III type recombinant collagen dressing.
Preferably, in (3), the stirring is performed at 600-800r/min for 3-5min at normal temperature.
Preferably, in (4), the heating is to 80-95 ℃, preferably 92 ℃.
Preferably, in (4), the incubation is for 30-60min.
Preferably, in (5), the triethanolamine is added after the temperature of mixture 3 is reduced to 50-60 ℃.
Preferably, in (6), the recombinant type III humanized collagen is added when the temperature of the mixture 4 is reduced to less than 45 ℃.
Preferably, the weight ratio of the recombinant type III humanized collagen to the purified water in the recombinant type III humanized collagen aqueous solution is 0.05-0.1:30.
the carrier in the invention can be selected from any one or more of gauze, non-woven fabrics and gel.
The invention also aims to provide an application of the III type recombinant collagen dressing in preparing a product with repairing and anti-aging effects.
Compared with the prior art, the invention has the technical advantages that:
(1) The invention adopts recombinant III type humanized collagen, forms a supercoiled structure with the broken collagen in the wound surface through intermolecular van der Waals force, and the reticular supercoiled structure can form a layer of protective film on the surface of damaged tissues to isolate and shield the skin wound surface. Meanwhile, the recombinant III type humanized collagen has better cell adhesion (the charged amino acid residues of the recombinant III type humanized collagen and the charges on the cell surface generate cell adhesion through physical charge absorption), and external support is provided for cells so as to promote repair of damaged parts. The recombinant III type humanized collagen can directly supplement III type collagen of wound surfaces, and the occurrence probability of scars is reduced.
(2) The theaflavin, the brown alginate oligosaccharides and the D- (+) -trehalose dihydrate have better synergistic effect, so that a physical barrier with air permeability is formed on the surface of a wound surface rapidly, and a carbomer thickener is utilized, so that the moist environment of the wound surface is fully ensured, a more stable, moist and good-air-permeability microenvironment is provided for wound surface healing, the microbial environment on the surface of the wound surface has good antibacterial, anti-inflammatory and antioxidant effects, a good function of scavenging free radicals in skin is realized, the damage of the free radicals to cells is avoided, the wound surface healing is accelerated, the wound surface healing time is shortened, the nursing function of the wound surface is achieved, the metabolism of the skin is promoted, the pigmentation is reduced, the soothing effect of the wound surface of the skin is enhanced, the irritation to the wound surface skin is effectively reduced, the capability of the skin to adapt to the environment is improved, and the secondary infection and anaphylactic reaction of the wound surface are avoided.
(3) The III type recombinant collagen dressing can be widely applied to nursing of non-chronic wounds (such as superficial wounds, postoperative suture wounds, mechanical wounds, small wounds, bruises, cut wound surfaces, puncture parts of puncture instruments, I-degree or shallow II-degree burn and scald wound surfaces, laser/photon/fruit acid skin replacement/micro plastic postoperative wound surfaces), has wider adaptability, can be singly used, and can also be matched with carriers such as gauze, non-woven fabrics and the like. The prepared skin wound dressing is subjected to animal skin irritation test, skin sensitization test and in-vitro cytotoxicity test respectively, and the results show that the skin wound dressing is safe and nontoxic.
Detailed Description
The present invention will be described by way of specific examples, to facilitate understanding and grasping of the technical solution of the present invention, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials can be obtained from commercial approaches unless specified, are pharmacopoeia standards or analytically pure, and have the same purchase sources without influencing test results.
Description of some of the reagents used in the present invention: recombinant humanized collagen III was purchased from Zhejiang and Synergic Biotechnology Inc., specification model: a BSS; brown alginate oligosaccharides were purchased from Qingdao Bozhi Hui biosciences limited (trade name) Short for the sake of brevity: AOS); carbomers are carbomers 940 (CAS 9007-20-9); xanthan gum (molecular weight 241.115,CAS 11138-66-2).
Example 1
A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.07 part of recombinant III-type humanized collagen, 0.15 part of D- (+) -trehalose dihydrate, 0.15 part of carbomer, 0.1 part of xanthan gum, 2.5 parts of butanediol, 2 parts of glycerol, 0.3 part of triethanolamine and 92 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Taking 30 parts of purified water, and dissolving the recombinant III type humanized collagen in the prescription amount to prepare a recombinant III type humanized collagen solution for later use;
(2) Separately weighing carbomer and the rest formula amount of purified water (62 parts), adding the carbomer into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring at 700r/min for 4min to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating to 92 ℃, homogenizing, and preserving heat for 40min to obtain a mixture 3;
(5) Cooling the mixture 3, adding triethanolamine into the mixture 3 when the temperature of the mixture 3 is reduced to 60 ℃, and stirring to obtain a mixture 4;
(6) When the temperature of the mixture 4 is reduced to below 45 ℃, adding the recombinant III type humanized collagen solution into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution;
(7) And (3) soaking the III type recombinant collagen dressing base solution obtained in the step (6) in a non-woven fabric to obtain the III type recombinant collagen dressing.
Example 2
The III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following raw materials in parts by weight: the preparation method comprises the following raw materials: 0.05 part of recombinant III-type humanized collagen, 1 part of D- (+) -trehalose dihydrate, 0.01 part of theaflavin, 0.2 part of brown alginate oligosaccharides, 0.15 part of carbomer, 1 part of xanthan gum, 1 part of butanediol, 5 parts of glycerol, 0.1 part of triethanolamine and 150 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Taking 30 parts of purified water, and dissolving the recombinant III type humanized collagen in the prescription amount to prepare a recombinant III type humanized collagen solution for later use;
(2) Separately weighing carbomer, theaflavin, brown alginate oligosaccharides and the remaining formula amount of purified water (120 parts), sequentially adding carbomer, theaflavin and brown alginate oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring at 600r/min for 5min to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating to 80 ℃, homogenizing, and preserving heat for 30min to obtain a mixture 3;
(5) Cooling the mixture 3, adding triethanolamine into the mixture 3 when the temperature of the mixture 3 is reduced to 50 ℃, and stirring to obtain a mixture 4;
(6) When the temperature of the mixture 4 is reduced to below 45 ℃, adding the recombinant III type humanized collagen solution into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution;
(7) And (3) soaking the III type recombinant collagen dressing base solution obtained in the step (6) in a non-woven fabric to obtain the III type recombinant collagen dressing.
Example 3
A III type recombinant collagen dressing with repairing and anti-aging effects comprises, by weight, 0.1 part of recombinant III type humanized collagen, 0.15 part of D- (+) -trehalose dihydrate, 0.05 part of theaflavin, 0.05 part of brown alginate oligosaccharides, 0.5 part of carbomer, 0.1 part of xanthan gum, 5 parts of butanediol, 1 part of glycerol, 0.5 part of triethanolamine and 130 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Taking 30 parts of purified water, and dissolving the recombinant III type humanized collagen in the prescription amount to prepare a recombinant III type humanized collagen solution for later use;
(2) Separately weighing carbomer, theaflavin, brown alginate oligosaccharides and the remaining formula amount of purified water (100 parts), sequentially adding carbomer, theaflavin and brown alginate oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring at 800r/min for 3min to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating to 95 ℃, homogenizing, and preserving heat for 60min to obtain a mixture 3;
(5) Cooling the mixture 3, adding triethanolamine into the mixture 3 when the temperature of the mixture 3 is reduced to 60 ℃, and stirring to obtain a mixture 4;
(6) When the temperature of the mixture 4 is reduced to below 45 ℃, adding the recombinant III type humanized collagen solution into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution;
(7) And (3) soaking the III type recombinant collagen dressing base solution obtained in the step (6) in a non-woven fabric to obtain the III type recombinant collagen dressing.
Example 4
A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.07 part of recombinant III-type humanized collagen, 0.15 part of D- (+) -trehalose dihydrate, 0.03 part of theaflavin, 0.1 part of brown alginate oligosaccharides, 0.15 part of carbomer, 0.1 part of xanthan gum, 2.5 parts of butanediol, 2 parts of glycerol, 0.3 part of triethanolamine and 95 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Taking 30 parts of purified water, and dissolving the recombinant III type humanized collagen in the prescription amount to prepare a recombinant III type humanized collagen solution for later use;
(2) Separately weighing carbomer, theaflavin, brown alginate oligosaccharides and the remaining formula amount of purified water (65 parts), sequentially adding carbomer, theaflavin and brown alginate oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring at 700r/min for 4min to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating to 92 ℃, homogenizing, and preserving heat for 40min to obtain a mixture 3;
(5) Cooling the mixture 3, adding triethanolamine into the mixture 3 when the temperature of the mixture 3 is reduced to 60 ℃, and stirring to obtain a mixture 4;
(6) When the temperature of the mixture 4 is reduced to below 45 ℃, adding the recombinant III type humanized collagen solution into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution;
(7) And (3) soaking the III type recombinant collagen dressing base solution obtained in the step (6) in a non-woven fabric to obtain the III type recombinant collagen dressing.
Comparative example 1
The difference compared to example 4 is only that the brown alginate is replaced with the same amount of theaflavin.
A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.07 part of recombinant III-type humanized collagen, 0.15 part of D- (+) -trehalose dihydrate, 0.13 part of theaflavin, 0.15 part of carbomer, 0.1 part of xanthan gum, 2.5 parts of butanediol, 2 parts of glycerol, 0.3 part of triethanolamine and 95 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Step (1) was performed as in example 4;
(2) Separately weighing carbomer, theaflavin and the rest formula amount of purified water (65 parts), sequentially adding the carbomer and the theaflavin into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) - (7) the steps (3) - (7) of example 4, preparing a type III recombinant collagen dressing base solution and the type III recombinant collagen dressing.
Comparative example 2
The difference compared to example 4 is only that the theaflavins are replaced with the same amount of brown alginate oligosaccharides.
A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.07 part of recombinant III-type humanized collagen, 0.15 part of D- (+) -trehalose dihydrate, 0.13 part of brown alginate oligosaccharides, 0.15 part of carbomer, 0.1 part of xanthan gum, 2.5 parts of butanediol, 2 parts of glycerol, 0.3 part of triethanolamine and 95 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Step (1) was performed as in example 4;
(2) Separately weighing carbomer, brown alginate oligosaccharides and the remaining formula amount of purified water (65 parts), sequentially adding carbomer and brown alginate oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) - (7) the steps (3) - (7) of example 4, preparing a type III recombinant collagen dressing base solution and the type III recombinant collagen dressing.
Comparative example 3
The only difference compared to example 4 is that epicatechin is used instead of theaflavins.
A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.07 part of recombinant III type humanized collagen, 0.15 part of D- (+) -trehalose dihydrate, 0.03 part of epicatechin, 0.1 part of brown alginate oligosaccharide, 0.15 part of carbomer, 0.1 part of xanthan gum, 2.5 parts of butanediol, 2 parts of glycerol, 0.3 part of triethanolamine and 95 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Step (1) was performed as in example 4;
(2) Separately weighing carbomer, epicatechin, brown alginate-oligose and the rest formula amount of purified water (65 parts), sequentially adding carbomer, epicatechin and brown alginate-oligose into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) - (7) the steps (3) - (7) of example 4, preparing a type III recombinant collagen dressing base solution and the type III recombinant collagen dressing.
Comparative example 4
The only difference compared to example 1 is that the same amount of brown alginate oligosaccharides was used instead of D- (+) -trehalose dihydrate.
A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.07 part of recombinant III-type humanized collagen, 0.15 part of brown alginate oligosaccharides, 0.15 part of carbomer, 0.1 part of xanthan gum, 2.5 parts of butanediol, 2 parts of glycerol, 0.3 part of triethanolamine and 92 parts of purified water.
The preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Step (1) is the same as in example 1;
(2) Separately weighing carbomer and the rest formula amount of purified water (62 parts), adding carbomer into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and brown alginate oligosaccharides, and stirring at 700r/min for 4min to obtain a mixture 2;
(4) - (7) the steps (4) - (7) of example 1, preparing a type III recombinant collagen dressing base solution and the type III recombinant collagen dressing.
Comparative example 5
The formulation described in CN115998939A was used, and diluted to an active ingredient content (the ingredients except for purified water were regarded as active ingredients) in the same manner as in example 1 of the present application, and an auxiliary material was prepared according to example 1 of the present application.
The III type recombinant collagen dressing comprises the following raw materials in parts by weight: 4 parts of recombinant III type humanized collagen; 2 parts of sodium hyaluronate; 3 parts of glycerol; 1 part of xanthan gum; 5 parts of glycerol caprylate; 3 parts of octanoyl hydroxamic acid; 2 parts of 1,2 hexanediol; 350 parts of purified water;
the preparation method comprises the following steps: sequentially dispersing sodium hyaluronate, glycerol, 1,2 hexanediol, recombinant III type humanized collagen, glycerol caprylate and xanthan gum in purified water, dispersing octanoyl hydroxamic acid into the purified water to obtain a mixed solution, emulsifying and homogenizing the mixed solution for 10min to obtain a III type recombinant collagen dressing base solution, and soaking non-woven fabrics by using the III type recombinant collagen dressing base solution to obtain the III type recombinant collagen dressing.
Effect test
1. Wound repair test
(1) 180 patients with no obvious skin wound infection during surgery or trauma are randomly selected, 56 men and 124 women are randomly divided into 9 groups with the age of 18-51 years, 20 patients in each group have no obvious difference in basic data, and P is more than 0.05, so that the patients can be compared;
(2) The treatment method comprises the following steps: after cleaning the skin damage part every day, the test group uses the distributed dressing respectively, and the dressing is applied for 1 time every day in the evening in the period of 1 to 10 days, and is applied for 1 time every other day in the evening after 10 days, and the application time is 20 minutes each time;
(3) Treatment criteria:
skin symptom score: the red spot, edema, exudation, stinging and pigmentation were marked 5, and each index was marked 0 and 1 respectively according to asymptomatic and symptomatic. For example, among the erythema indices, no erythema is noted as 0 score, erythema is noted as 1 score, and so on to the indices of edema, exudation, stinging, pigmentation. The sum of the 5 index scores is the total value of the skin symptom scores of each patient.
Efficacy evaluation criteria: the traditional Chinese medicine is divided into four criteria of cure, obvious effect, effective and ineffective.
Efficacy index = [ (pre-treatment integral-post-treatment integral)/(pre-treatment integral ] ×100%).
Analyzing the curative effect index after 10 days of treatment; and (3) healing: the curative effect index is more than or equal to 95%; the effect is shown: the curative effect index is 70-94%; the method is effective: the curative effect index is 30-69%; invalidation: the curative effect index is less than 30 percent.
II, wound healing time: according to the method, the average wound healing time (days) of patients in each experimental group and control group is counted; average number of days of healing = sum of days of healing for each patient/patient population.
III, detecting skin physiological function indexes: the average moisture content of the stratum corneum after curing of patients in each experimental group is detected by a noninvasive skin physiological function tester (MC 760 of the German CK company), and the testing method comprises the following steps: and (3) measuring under the conditions of constant temperature and constant humidity, wherein the room temperature is 23-26 ℃, the relative humidity is 40% -60%, respectively detecting non-skin damage parts of cheeks of a tested person, cleaning skin to be tested before detection, and entering a test environment for 30min in advance for testing.
(4) The treatment results are shown in table 1 below:
TABLE 1 wound repair test results
From the above data, it is clear that example 1 of the present invention has a significant advantage in terms of therapeutic effect as compared with comparative examples 4 and 5. This demonstrates that the formulation of example 1 of the present invention has a better healing effect advantage compared to the formulation of prior art CN115998939A, and that the recombinant type iii humanized collagen and D- (+) -trehalose dihydrate of the present invention have a synergistic effect as shown in the data of comparative example 4.
From the comparison of the data of examples 2-4 and comparative examples 1-3, examples 2-4 of the present invention are significantly superior to comparative examples 1-3 in terms of therapeutic effect, and from the data of example 4 and comparative examples 1-3, it can be seen that the skin therapeutic effect is deteriorated when only theaflavins and brown alginate oligosaccharides are replaced with another ingredient without changing the total content of active ingredients; meanwhile, when theaflavin is replaced by epicatechin with the same effect, the effect is also poor, which shows that the two components of theaflavin and brown alginate oligosaccharides act together with other components, and a better synergistic effect can be achieved.
2. DPPH radical scavenging test
Test reagent: DPPH (available from sigma aldrich (china) chemical limited, product CAS number 1898-66-4); the DPPH solution is dissolved in absolute ethanol and has a concentration of 6×10 -5 DPPH solution in mol/L.
(1) Taking 0.5mL of the III type recombinant collagen dressing base solution obtained in the examples 1-4 and the comparative examples 1-5, and mixing with 2.5mL of DPPH solution to obtain test groups (namely, the examples 1-4 and the comparative examples 1-5);
(2) Mixing 0.5mL of absolute ethyl alcohol with 2.5mL of DPPH solution to obtain a blank group;
(3) After standing at room temperature in dark for 30min, determining A of each group simultaneously 519 (absorbance A value at 519nm of the maximum absorption wavelength); test group a; blank groups are denoted as A0, and each group of tests was performed in triplicate, and the results averaged.
(4) DPPH free radical clearance calculation formula: clearance% = (blank A0-experiment a)/blank A0, test results are shown in table 2.
TABLE 2DPPH radical scavenging test results
From the above data, it is clear that example 1 of the present invention has a significant advantage in radical scavenging ability as compared with comparative examples 4 and 5. This demonstrates that the formulation of example 1 of the present invention has better antioxidant advantage compared to the formulation of prior art CN115998939A, and that the recombinant type iii humanized collagen and D- (+) -trehalose dihydrate of the present invention have a synergistic effect as shown in the data of comparative example 4.
As can be seen from the comparison of the data of examples 2-4 and comparative examples 1-3, examples 2-4 of the present invention are significantly superior to comparative examples 1-3 in the effect of scavenging free radicals, and as can be seen from the data of examples 4 and comparative examples 1-3, the oxidation resistance is deteriorated when only theaflavins and brown algae oligosaccharides are replaced with another component without changing the total content of active ingredients; meanwhile, when theaflavin is replaced by epicatechin with the same effect, the effect is also poor, which shows that the two components of theaflavin and brown alginate oligosaccharides act together with other components, and a better synergistic effect can be achieved.
Therefore, the III type recombinant collagen dressing provided by the invention has better repairing, antioxidation and anti-aging effects.
The foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (5)
1. A III type recombinant collagen dressing with repairing and anti-aging effects comprises the following raw materials in parts by weight:
0.05-0.1 part of recombinant III-type humanized collagen, 0.15-1 part of D- (+) -trehalose dihydrate, 0.01-0.05 part of theaflavin, 0.05-0.2 part of brown alginate oligosaccharides, 0.15-0.5 part of carbomer, 0.1-1 part of xanthan gum, 1-5 parts of butanediol, 1-5 parts of glycerol, 0.1-0.5 part of triethanolamine and 90-180 parts of purified water;
the preparation method of the III type recombinant collagen dressing with the repairing and anti-aging effects comprises the following steps:
(1) Taking part of purified water, dissolving recombinant III type humanized collagen in a prescription amount, and preparing a recombinant III type humanized collagen solution for later use;
(2) Respectively weighing carbomer, theaflavin, brown algae oligosaccharides and the remaining formula amount of purified water, sequentially adding carbomer, theaflavin and brown algae oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating, homogenizing and preserving heat to obtain a mixture 3;
(5) Adding triethanolamine into the mixture 3, and stirring to obtain a mixture 4;
(6) Adding the recombinant III type humanized collagen solution in the step (1) into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution, and adding the base solution into a carrier to obtain the III type recombinant collagen dressing.
2. The type III recombinant collagen dressing of claim 1, comprising the following raw materials in parts by weight:
0.05-0.09 part of recombinant III-type humanized collagen, 0.15-0.5 part of D- (+) -trehalose dihydrate, 0.01-0.03 part of theaflavin, 0.05-0.1 part of brown algae oligosaccharide, 0.15-0.45 part of carbomer, 0.1-0.5 part of xanthan gum, 2-3 parts of butanediol, 1-3 parts of glycerin, 0.2-0.4 part of triethanolamine and 92-150 parts of purified water.
3. A method for preparing a type III recombinant collagen dressing having an anti-aging effect according to any one of claims 1 to 2, comprising the steps of:
(1) Taking part of purified water, dissolving recombinant III type humanized collagen in a prescription amount, and preparing a recombinant III type humanized collagen solution for later use;
(2) Respectively weighing carbomer, theaflavin, brown algae oligosaccharides and the remaining formula amount of purified water, sequentially adding carbomer, theaflavin and brown algae oligosaccharides into the purified water, homogenizing to obtain a mixture 1, and standing for later use;
(3) Weighing glycerol, butanediol, xanthan gum and D- (+) -trehalose dihydrate, and stirring to obtain a mixture 2;
(4) Adding the mixture 2 into the mixture 1, heating, homogenizing and preserving heat to obtain a mixture 3;
(5) Adding triethanolamine into the mixture 3, and stirring to obtain a mixture 4;
(6) Adding the recombinant III type humanized collagen solution in the step (1) into the mixture 4, stirring and homogenizing to obtain III type recombinant collagen dressing base solution, and adding the base solution into a carrier to obtain the III type recombinant collagen dressing.
4. The method for preparing a type III recombinant collagen dressing with repair and anti-aging effects according to claim 3, wherein the weight ratio of the recombinant type III humanized collagen in the recombinant type III humanized collagen solution to purified water is 0.05-0.1:30.
5. use of a recombinant collagen type III dressing according to any one of claims 1-2 for the preparation of a product having a restorative anti-aging effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310841771.2A CN116688212B (en) | 2023-07-11 | 2023-07-11 | III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310841771.2A CN116688212B (en) | 2023-07-11 | 2023-07-11 | III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116688212A CN116688212A (en) | 2023-09-05 |
| CN116688212B true CN116688212B (en) | 2024-03-08 |
Family
ID=87824006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310841771.2A Active CN116688212B (en) | 2023-07-11 | 2023-07-11 | III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116688212B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117982710A (en) * | 2024-02-18 | 2024-05-07 | 韩伟东 | Preparation method of recombinant double-protein medical dressing |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1738738A1 (en) * | 2005-06-04 | 2007-01-03 | Cognis IP Management GmbH | Microcapsules |
| CN101886097A (en) * | 2010-06-18 | 2010-11-17 | 江苏德和生物科技有限公司 | Preparation process for high purity theaflavin and application thereof in preparing anti-influenza virus medicines |
| CN113813439A (en) * | 2021-11-04 | 2021-12-21 | 湖南愈尔美医疗科技有限公司 | Preparation method of medical yeast recombinant III-type collagen dressing |
| CN114191597A (en) * | 2021-12-16 | 2022-03-18 | 湖南银华棠医药科技有限公司 | Liquid dressing for repairing skin wound surface and preparation method and application thereof |
| CN114904046A (en) * | 2022-06-09 | 2022-08-16 | 江苏扬子江医疗科技股份有限公司 | Recombinant III-type humanized collagen composition and preparation method and application thereof |
| CN115475277A (en) * | 2022-10-27 | 2022-12-16 | 河南国械医疗器械有限公司 | Recombined III-type humanized triple-helical-structure collagen dressing |
| CN115998939A (en) * | 2022-11-23 | 2023-04-25 | 重庆正仁医疗器械有限公司 | Medical recombinant III type humanized collagen paste |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2433029A (en) * | 2005-12-09 | 2007-06-13 | Ethicon Inc | Wound dressings comprising oxidized cellulose and human recombinant collagen |
| CN113577055B (en) * | 2021-07-26 | 2022-10-04 | 安徽农业大学 | Theaflavin composition for promoting wound healing and preparation method and application thereof |
-
2023
- 2023-07-11 CN CN202310841771.2A patent/CN116688212B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1738738A1 (en) * | 2005-06-04 | 2007-01-03 | Cognis IP Management GmbH | Microcapsules |
| CN101886097A (en) * | 2010-06-18 | 2010-11-17 | 江苏德和生物科技有限公司 | Preparation process for high purity theaflavin and application thereof in preparing anti-influenza virus medicines |
| CN113813439A (en) * | 2021-11-04 | 2021-12-21 | 湖南愈尔美医疗科技有限公司 | Preparation method of medical yeast recombinant III-type collagen dressing |
| CN114191597A (en) * | 2021-12-16 | 2022-03-18 | 湖南银华棠医药科技有限公司 | Liquid dressing for repairing skin wound surface and preparation method and application thereof |
| CN114904046A (en) * | 2022-06-09 | 2022-08-16 | 江苏扬子江医疗科技股份有限公司 | Recombinant III-type humanized collagen composition and preparation method and application thereof |
| CN115475277A (en) * | 2022-10-27 | 2022-12-16 | 河南国械医疗器械有限公司 | Recombined III-type humanized triple-helical-structure collagen dressing |
| CN115998939A (en) * | 2022-11-23 | 2023-04-25 | 重庆正仁医疗器械有限公司 | Medical recombinant III type humanized collagen paste |
Non-Patent Citations (4)
| Title |
|---|
| 潘道东.功能性食品添加剂.北京：中国轻工业出版社,2006,第394页. * |
| 秦益民.海洋功能性食品配料 褐藻多糖的功能和应用.北京：中国轻工业出版社,2019,第53-54页. * |
| 褐藻胶低聚糖的保水性和抗氧化功能研究;许小娟;付晓婷;段德麟;许加超;高昕;;农产品加工(学刊)(第08期);全文 * |
| 重组胶原蛋白敷料的生物相容性及动物有效性研究;何越;侯增淼;高恩;杨小琳;赵金礼;;中国美容整形外科杂志(第08期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116688212A (en) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016204958A1 (en) | Petrolatum-based compositions comprising cationic biocides | |
| CN116688212B (en) | III type recombinant collagen dressing with repairing and anti-aging effects and preparation method and application thereof | |
| US9962402B2 (en) | Healing composition for topical application | |
| CN113975197B (en) | Composition containing sodium polyglutamate and dressing applied by composition | |
| CN104622897A (en) | Skin moisturizer for treating skin disease and preparation method of skin moisturizer | |
| CN117427209B (en) | Medical mussel mucin liquid dressing for rapidly repairing sensitive muscles and preparation method thereof | |
| CN112107724A (en) | Liquid dressing and preparation method thereof | |
| US20210260096A1 (en) | Pharmaceutical composition for treating wound or activating skin, containing beta-glucan, glycitin, and 4',6,7-trimethoxyisoflavone | |
| CN110200988A (en) | A kind of scar repair agent and preparation method thereof | |
| CN102755414B (en) | Traditional Chinese medicine ointment for trauma wound and preparation method thereof | |
| CN114601959A (en) | Medical skin care dressing and preparation method and application thereof | |
| CN113616587A (en) | Aerosol for repairing skin after being exposed to sun and preparation method thereof | |
| CN107982300B (en) | Spray and preparation method and application thereof | |
| CN113274337A (en) | Medical skin repairing and nursing film and preparation method thereof | |
| CN112206281A (en) | Anti-infection wound repair pharmaceutical composition, preparation method and application thereof | |
| CN113855849A (en) | Dressing composition and preparation method and application thereof | |
| CN104027298A (en) | Lentinan gelata and preparation method thereof | |
| KR20140114617A (en) | Hydrogel patch containing the curcumin for wound healing and preparation method thereof | |
| CN115554465B (en) | Freeze-dried absorbable collagen-based medical dressing and preparation method thereof | |
| CN114886794B (en) | Composition with anti-inflammatory and antioxidant effects and application thereof | |
| CN111281940B (en) | Scar-removing composition and preparation method and application thereof | |
| CN106902348B (en) | Nail nursing cream for tumor patients | |
| CN115737902A (en) | Medical recombinant III-type humanized collagen gel | |
| CN117045844A (en) | Dressing containing polysaccharide and preparation method and application thereof | |
| CN117085059A (en) | External Mongolian medicine for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |